![CMS-medicare-AHA-comment](/sites/default/files/2018-05/CMS-medicare-AHA-comment.jpg)
The National Institute of Allergy and Infectious Diseases has launched a clinical trial to evaluate a potential COVID-19 treatment regimen for hospitalized patients that combines remdesivir with interferon beta-1a, a medication approved to treat multiple sclerosis that laboratory studies suggest may benefit patients with COVID-19. T